From Wikipedia, the free encyclopedia
|Systematic (IUPAC) name|
|Molar mass||309.33 g/mol|
CRL-40,940 (also known as flmodafinil, bisfluoromodafinil and lauflumide) is a selective dopaminergic reuptake inhibitor, and is the bisfluoro analog of the wakefulness-promoting agent (or eugeroic) modafinil and has been sold online as a designer drug. Its inventors showed that it is more effective than modafinil and adrafinil in their indications with fewer side effects, and was patented in 2013. Phase I clinical trials have been underway since December 2015.
- Louis Lafon (28 January 1986). "Patent CA 1199916 A1 - Benzhydrylsulfinylacetamide derivatives". Retrieved 25 July 2015.
- Jianjing Cao; Thomas E. Prisinzano; Oluyomi M. Okunola; Theresa Kopajtic; Matthew Shook; Jonathan L. Katz; Amy Hauck Newman (January 2011). "SARs at the Monoamine Transporters for a Novel Series of Modafinil Analogues". ACS Medicinal Chemistry Letters. 2 (1): 48–52. doi:10.1021/ml1002025. PMC . PMID 21344069.
- Eric Konofal (7 November 2013). "Patent US 20130295196 A1 - Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof". Retrieved 25 July 2015.
- Louis Lafon (18 December 1984). "Patent US 4489095 A - Halogenobenzhydrylsulfinylacetohydroxamic acids". Retrieved 25 July 2015.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|